Spectrum appoints Amgen vet Ken Keller as COO

Thursday, September 13, 2012 08:00 AM

Spectrum Pharmaceuticals, a biotechnology company focused on hematology and oncology, has appointed Ken Keller as executive vice president and COO. Keller will have global responsibility for leading commercial operations, medical and clinical development and pharmaceutical operations.

He brings more than 20 years of experience in the pharmaceutical industry ranging from sales and marketing leadership, general management and joint venture leadership in several therapeutic areas, including oncology, rheumatology, dermatology and primary care. Prior to joining Spectrum, Keller spent 21 years at Amgen. His most recent role was vice president and general manager, bone health business unit, Amgen. During his career at Amgen, Keller has been the marketing lead or the general manager for four of the world's top selling biologic medicines Neupogen, Neulasta, Aranesp and Enbrel. He also has significant international experience, as managing director for Amgen's U.K. and Ireland affiliate.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs